Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
75 76 Next >
News headline image
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
News headline image
Two Sectors Just Tried And Failed - And That’s Great For Us ↗
Technology and healthcare have both tried for a breakout and failed, courtesy of massive economic forces rocking the boat. 
Via Talk Markets
Topics Stocks / Equities
News headline image
A Potential Challenger For AstraZeneca's Blockbuster Lung Cancer Drug? ↗
AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug. 
Via Benzinga
News headline image
Eventful Monday For AstraZeneca - What's Going On? ↗
AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for small cell lung cancer treatment. 
Via Benzinga
News headline image
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details ↗
AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion deal includes an initial payment of $425 million, with additional contingent... 
Via Benzinga
News headline image
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
From AstraZeneca
Via Business Wire
News headline image
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst ↗
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets. 
Via Benzinga
News headline image
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity ↗
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025. 
Via Benzinga
News headline image
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion ↗
The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug. 
Via Investor's Business Daily
News headline image
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal ↗
Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales. 
Via Benzinga
News headline image
One Week Is Currently Like A Decade In These Markets ↗
It’s what they call a “low dollar market” in that general conditions aren’t easy and there aren’t many slam dunk no-brainer setups. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Is ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) suited for quality investing? ↗
A fundamental analysis of (NASDAQ:AZN): This article explores why quality investors may have a look at ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) 
Via Chartmill
News headline image
AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients ↗
AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong trend in overall survival. 
Via Benzinga
News headline image
IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers
From AstraZeneca
Via Business Wire
News headline image
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst ↗
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis. 
Via Benzinga
News headline image
Inside The Quantum Computing Crash Triggered By Nvidia CEO — And What His Upcoming 'Quantum Day' May Bring ↗
Nvidia's CEO threw cold water on quantum computing by scoffing at its near-term utility. Quantum execs are sharpening their arguments. 
Via Investor's Business Daily
News headline image
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials ↗
 
Via Benzinga
News headline image
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis ↗
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial. 
Via Benzinga
News headline image
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire
News headline image
IonQ CEO Fires Back At Nvidia's Jensen Huang: 'We Remain The 800 Pound Guerrilla' ↗
IonQ CEO Niccolo De Masi is confident that quantum computing will soon be the third leg of computing. With major partnerships and predicted GAAP revenue, IonQ is poised to be a leader in the industry. 
Via Benzinga
News headline image
Snowflake Expands Microsoft, OpenAI Partnership: Will Include Other Prominent Models Like Anthropic's Claude, Meta's Llama, And DeepSeek ↗
Snowflake unveiled its deeper partnership with Microsoft Corp during its earnings call and introduced its new AI agent Cortex. 
Via Benzinga
Topics Artificial Intelligence Earnings
News headline image
AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With Widely Cancer Medicines ↗
AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer. 
Via Benzinga
News headline image
Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Ranked: 10 Largest Companies In The U.S., Europe, And China ↗
The top nine American companies by market cap are all worth more than a trillion dollars. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Synchronicity: Denying The Unexplainable ↗
Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph? 
Via Talk Markets
Topics Stocks / Equities
News headline image
3 Magnificent Growth Stocks to Buy Right Now ↗
Via The Motley Fool
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million ↗
FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent. 
Via Benzinga
News headline image
AZN Deadline: Rosen Law Firm Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Big Money Is Betting On Europe, Should You? 3 ETFs To Watch ↗
European fund managers are bullish on stocks, with 3 top ETFs to consider: SPDR EURO STOXX 50 (FEZ), Vanguard FTSE Europe (VGK), Xtrackers MSCI EAFE Hedged Equity (DBEF) 
Via Benzinga
Topics ETFs
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.